EUVIMEDEUVIMED entdecken
Crossref

Iodine-125 Brachytherapy Combined with Biliary Stenting in Advanced Pancreatic Cancer: A Clinical Application Study

Huiyi Sun, Yirou Zhou, Guoping Li, Feihang Wang, Zihao Huo, Junqi Shuai, Zhiping Yan, Lingxiao Liu, Yi Chen

Academic Radiology · 2026-04 · 33 (4) · 1355-1367

DOI: 10.1016/j.acra.2026.01.047 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Academic Radiology, 2026-04. Verfasst von Huiyi Sun und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Radiology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032, China (H.S., Y.Z., G.L., F.W., Z.H.,…. Hauptthemen laut MEDLINE: Brachytherapy, Pancreatic Neoplasms, Iodine Radioisotopes, Stents. Die Arbeit nennt 45 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Fudan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RATIONALE AND OBJECTIVES: This study aims to investigate the impact of iodine-125 intraluminal brachytherapy on stent patency time (SPT) and overall survival (OS) in patients with advanced pancreatic cancer complicated by obstructive jaundice, which may provide evidence for optimizing multimodal interventional strategies for patients with pancreatic cancer. METHODS: This retrospective study enrolled 262 patients with advanced pancreatic cancer complicated by obstructive jaundice who had underwent metallic biliary stent implantation. Patients were stratified into the 125I group and the control group. A 1:1 propensity score matching (PSM) was performed using a caliper width of 0.2 standard deviations of the propensity score. RESULTS: After 1 month of biliary stent implantation, significant reductions of serum bilirubin, transaminases, and CA19-9 levels compared to predrainage were observed in this study. A median SPT of 7.63 months (95% CI 7.10-8.16), a stent restenosis rate of 36.2%, and a median OS of 9.40 months (95% CI 9.11-9.69) was demonstrated in the entire cohort demonstrated. After 1:1 PSM (62 patients per group), the 125 I group showed a significantly longer median SPT (9.44 months vs. 6.21 months, P < 0.001) and lower stent restenosis rate (17.7% vs. 43.5%, P = 0.002) compared to the control group. However, no significant OS difference was observed between groups (10.59 months vs. 9.07 months, P = 0.248). Cox analysis suggested that intratumoral brachytherapy (HR 0.382, P < 0.001) was an independent protective factor for SPT; post-stent Eastern Cooperative Oncology Group (ECOG) 2 score (HR 1.572, P = 0.019) was an independent risk factor for SPT. The independent risk factors for OS included post-stent ECOG 2 score (HR 1.469, P = 0.042) and post-stent CA19-9≥500 ku/L (HR 1.322, P = 0.046). CONCLUSION: Biliary stent combined with iodine-125 intraluminal brachytherapy significantly prolonged SPT compared to stent-alone in patients with advanced pancreatic cancer complicated by obstructive jaundice, although it did not significantly improve survival outcomes. Higher ECOG performance score and higher CA19-9 level after jaundice reduce were associated with poor prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BrachytherapyPancreatic NeoplasmsIodine RadioisotopesStentsJaundice, ObstructiveHumansFemaleMaleAgedRetrospective StudiesMiddle AgedTreatment OutcomeSurvival RateCombined Modality TherapyRisk FactorsAged, 80 and over

Stichwörter der Autor:innen

Biliary stentIodine-125 intraluminal brachytherapy Advanced pancreatic CancerObstructive jaundice

Substanzen

Iodine RadioisotopesIodine-125

Autor:innen und Institutionen

  • Department of Interventional Radiology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032, China (H.S., Y.Z., G.L., F.W., Z.H., J.S., Z.Y., L.L., Y.H.); Shanghai Institute of Medical Imaging, Shang…

Förderung

  • National Key Research and Development Program of China
  • Fudan University

Zitieren

APA

Sun, H., Zhou, Y., Li, G., Wang, F., Huo, Z., Shuai, J., Yan, Z., Liu, L., & Chen, Y. (2026). Iodine-125 Brachytherapy Combined with Biliary Stenting in Advanced Pancreatic Cancer: A Clinical Application Study. Academic Radiology, 33(4), 1355-1367. https://doi.org/10.1016/j.acra.2026.01.047

Vancouver

Sun H, Zhou Y, Li G, Wang F, Huo Z, Shuai J, et al. Iodine-125 Brachytherapy Combined with Biliary Stenting in Advanced Pancreatic Cancer: A Clinical Application Study. Academic Radiology. 2026;33(4):1355-1367. doi:10.1016/j.acra.2026.01.047

BibTeX
@article{Sun2026,
  author = {Sun, Huiyi and Zhou, Yirou and Li, Guoping and Wang, Feihang and Huo, Zihao and Shuai, Junqi and Yan, Zhiping and Liu, Lingxiao and Chen, Yi},
  title = {Iodine-125 Brachytherapy Combined with Biliary Stenting in Advanced Pancreatic Cancer: A Clinical Application Study},
  journal = {Academic Radiology},
  year = {2026},
  volume = {33},
  number = {4},
  pages = {1355--1367},
  doi = {10.1016/j.acra.2026.01.047}
}
Kostenlos starten →